
Insulet (PODD) Stock
Leading maker of tubeless insulin pumps and consumables. Here's the price, business snapshot, and what's worth knowing about Insulet in November 2026.
Insulet Corporation (PODD) is a medical‑device company best known for its Omnipod tubeless insulin pump system, aimed at people with type 1 and insulin‑dependent type 2 diabetes. The business model centres on device sales and recurring pod consumables, with supplementary software and services that support automated insulin delivery. With a market capitalisation of roughly $23.2 billion, growth prospects hinge on rising adoption of insulin‑delivery technology, tighter integration with continuous glucose monitoring and expansion into international markets. Key investor considerations include manufacturing scale‑up, reimbursement and regulatory pathways, competition from established pump makers and integrated diabetes platforms, and execution risk around new product roll‑outs. Financial performance can be variable and past performance is not a guarantee of future returns. This is general educational information only and not personal advice; investors should assess suitability for their own circumstances and may wish to consult a regulated financial adviser.
Why It’s Moving

Insulet Faces Analyst Downgrade Amid Technical Breakout and Conference Presentation
- A major Wall Street analyst revised their outlook on Insulet to bearish, joining a list of recent downgrades that has pressured sentiment despite prior positive momentum.
- The stock demonstrated technical strength by surpassing resistance at the 20-day moving average, suggesting a short-term bullish trend had emerged before the rating change.
- Company leadership participated in the Jefferies Global Healthcare Conference, offering investors direct insights into operational strategies amid ongoing debates about its status as a top long-term growth pick.

Insulet Faces Analyst Downgrade Amid Technical Breakout and Conference Presentation
- A major Wall Street analyst revised their outlook on Insulet to bearish, joining a list of recent downgrades that has pressured sentiment despite prior positive momentum.
- The stock demonstrated technical strength by surpassing resistance at the 20-day moving average, suggesting a short-term bullish trend had emerged before the rating change.
- Company leadership participated in the Jefferies Global Healthcare Conference, offering investors direct insights into operational strategies amid ongoing debates about its status as a top long-term growth pick.
Six-Month Growth Performance
When is the next earnings date for INSULET CORPORATION (PODD)?
No confirmed upcoming earnings date has been announced for PODD as of November 16, 2026. Based on the company's historical reporting pattern, which typically follows a quarterly cycle with reports occurring approximately three months after the previous release, the next report is expected in February 2027. This anticipated release will likely cover the fourth quarter and full fiscal year results for 2026.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Insulet's stock with a target price of $233.63, indicating strong growth potential.
Financial Health
Insulet Corporation is performing well with strong revenue, cash flow, and profit margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Growth from Adoption
Increasing uptake of insulin‑delivery technology could drive revenue through devices and recurring pods, though adoption rates and reimbursement vary by market.
International Expansion
Rolling out into new regions offers scale potential, balanced against regulatory approvals, local reimbursement and distribution challenges.
Innovation & Partnerships
Integration with continuous glucose monitors and progress toward automated insulin delivery can be strategic catalysts, yet execution and competition are material risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.